https://doi.org/10.4081/monaldi.2022.2314
Clinical course of COPD in patients with Arg16Gly (rs1042713) polymorphism of ADRB2 gene
Submitted: May 7, 2022
Accepted: September 2, 2022
Published: September 13, 2022
Accepted: September 2, 2022
Abstract Views: 949
PDF: 332
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
The ADBR2 gene has been studied for its possible relationship with the development and clinical course of chronic obstructive pulmonary disease (COPD), including response to beta-2 agonists, with existing data being contentious on the subject. So, the purpose of this study was to look into the potential impact of the arginine-16-glycine (Arg16Gly) polymorphism on the clinical course and drug utilization in COPD patients. Data show that patients with Arg16Arg have a lower number of hospital admissions for exacerbations (p=0.048), but only in the total number of exacerbations, including those treated out-patients (p=0.086). Each glycine (Gly) copy was associated with a higher number of exacerbations (OR: 0.25; 95% CI: 0.00-055; p=0.048). The number of exacerbations after LABA/LAMA treatment was similar across groups, indicating that all ADRB2 variants responded well to the treatment. Furthermore, there were no statistically significant differences in mMRC and CAT values across all study visits. Interestingly, groups differed in their use of antibiotics (AB) at all visits, with Arg16Arg being associated with the least amount of AB use. There was also a link discovered between clycine copies and increased use of glucocorticoids. As a result, Arg16Gly is involved in the clinical course of COPD as well as the utilization of drug groups. Based on the findings, we can speculate that the cross-talk between the ADRB2 gene and the corticosteroid receptor is altered in patients with the Gly16Gly genotype.
Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2020 Report. Available from: https://www.goldcopd.org/wp-content/uploads/2019/12/GOLD-2020-FINAL-ver1.2-03Dec19_WMV.pdf
Burden of Obstructive Lung Disease (BOLD) [Internet]. Home page. Available from: https://www.boldstudy.org/
Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-base burden of obstructive lung disease study. Chest 2011;139:752-63.
DOI: https://doi.org/10.1378/chest.10-1253
Blanco I, Diego I, Bueno P, et al. Geographic distribution of COPD prevalence in the world displayed by Geographic Information System maps. Eur Respir J 2019;54:1900610.
DOI: https://doi.org/10.1183/13993003.00610-2019
GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;385:117-71.
DOI: https://doi.org/10.1016/S0140-6736(14)61682-2
Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:297-412.
DOI: https://doi.org/10.1183/09031936.06.00025805
Gaddam S, Gunukula SK, Lohr JW, Arora P. Prevalence of chronic kidney disease in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. BMC Pulm Med 2016;16:158.
DOI: https://doi.org/10.1186/s12890-016-0315-0
Janson C, Johansson G, Ställberg B, et al. Identifying the associated risks of pneumonia in COPD patients: ARCTIC an observational study. Respir Res 2018;19:172.
DOI: https://doi.org/10.1186/s12931-018-0868-y
Morgan AD, Zakeri R, Quint JK. Defining the relationship between COPD and CVD: what are the implications for clinical practice? Ther Adv Respir Dis 2018;12:1753465817750524.
DOI: https://doi.org/10.1177/1753465817750524
Rasmussen SM, Brok J, Backer V, et al. Association between chronic obstructive pulmonary disease and type 2 diabetes: A systematic review and meta-analysis. COPD 2018;15:526-35.
DOI: https://doi.org/10.1080/15412555.2018.1532495
Silverman EK. Genetics of COPD. Annu Rev Physiol 2020;82:413-31.
DOI: https://doi.org/10.1146/annurev-physiol-021317-121224
Vacca G, Schwabe K, Dück R, et al. Polymorphisms of the beta2 adrenoreceptor gene in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009;3:3-10.
DOI: https://doi.org/10.1177/1753465809102553
Karimi L, Lahousse L, Ghanbari M, et al. β2-adrenergic receptor (ADRB2) gene polymorphisms and risk of COPD exacerbations: The Rotterdam study. J Clin Med 2019;8:1835.
DOI: https://doi.org/10.3390/jcm8111835
Stupnytska G, Gorovenko N, Podolska S, et al. Association of the ADRB2 gene polymorphic variant C79G (rs1072714) with the course of chronic obstructive pulmonary disease in obese and non-obese patients. CBU Int Conf Proce 2018;6:960-5.
DOI: https://doi.org/10.12955/cbup.v6.1278
Gorovenko NG, Stupnytska GY, Podolskaya SV. Polymorphic variants of ADRB2, NR3C1, MDR1 genes as possible predictors of efficacy of combined therapy laba + ICS in patients with chronic obstructive pulmonary disease. Pharma Innov 2014;3:10-4.
Hizawa N, Makita H, Nasuhara Y, et al. Beta2-adrenergic receptor genetic polymorphisms and short-term bronchodilator responses in patients with COPD. Chest 2007;132:1485-92.
DOI: https://doi.org/10.1378/chest.07-1103
Kim WJ, Oh YM, Sung J, et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381-6.
Katsarou MS, Karathanasopoulou A, Andrianopoulou A, et al. Beta 1, beta 2 and beta 3 adrenergic receptor gene polymorphisms in a southeastern European population. Front Genet 2018.28;9:560.
DOI: https://doi.org/10.3389/fgene.2018.00560
Rabe KF, Fabbri LM, Israel E, et al. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial. Lancet Respir Med 2014;2:44-53.
DOI: https://doi.org/10.1016/S2213-2600(13)70248-0
Ingebrigtsen TS, Vestbo J, Rode L, et al. β2-adrenergic genotypes and risk of severe exacerbations in COPD: a prospective cohort study. Thorax 2019;74:934-40.
DOI: https://doi.org/10.1136/thoraxjnl-2018-212340
Bleecker ER, Meyers DA, Bailey WC, et al. ADRB2 polymorphisms and budesonide/formoterol responses in COPD. Chest 2012;142:320-8.
DOI: https://doi.org/10.1378/chest.11-1655
Kim WJ, Oh YM, Sung J, et al. Lung function response to 12-week treatment with combined inhalation of long-acting beta2 agonist and glucocorticoid according to ADRB2 polymorphism in patients with chronic obstructive pulmonary disease. Lung 2008;186:381-6.
DOI: https://doi.org/10.1007/s00408-008-9103-9
Yelensky R, Li Y, Lewitzky S, et al. A pharmacogenetic study of ADRB2 polymorphisms and indacaterol response in COPD patients. Pharmacogenomics J 2012;12:484-8.
DOI: https://doi.org/10.1038/tpj.2011.54
Schmidt P, Holsboer F, Spengler D. Beta(2)-adrenergic receptors potentiate glucocorticoid receptor transactivation via G protein beta gamma-subunits and the phosphoinositide 3-kinase pathway. Mol Endocrinol 2001;15:553-64.
DOI: https://doi.org/10.1210/mend.15.4.0613
How to Cite
Dmytriiev, Kostiantyn, Yuriy Mostovoy, Nataliia Slepchenko, and Yuliia Smereka. 2022. “Clinical Course of COPD in Patients With Arg16Gly (rs1042713) Polymorphism of <em>ADRB2< em> Gene”. Monaldi Archives for Chest Disease 93 (2). https://doi.org/10.4081/monaldi.2022.2314.
Copyright (c) 2022 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Similar Articles
- Carlos A. Jiménez-Ruiz, Marcos Garcia Rueda, Manuel A. Martinez Muñiz, Jacobo Sellarés, Maria A. Jiménez-Fuentes, Lourdes Lázaro Asegurado, Esther RodrÃguez Gonzalez, Concepción Rodriguez Garcia, Oriol Armengol, Emilia Abad, Teresa Peña, Adolfo Domenech del Rio, Juan A. Riesco Miranda, Varenicline in smokers with severe or very severe COPD after 24 weeks of treatment. A descriptive analysis: VALUE study , Monaldi Archives for Chest Disease: Vol. 87 No. 3 (2017)
- M. Lusuardi, C. Lucioni, F. De Benedetto, S. Mazzi, C.M. Sanguinetti, C.F. Donner, GOLD severity stratification and risk of hospitalisation for COPD exacerbations , Monaldi Archives for Chest Disease: Vol. 69 No. 4 (2008): Pulmonary series
- Abhishekl Agarwal, Sakshi Batra, Rajendra Prasad, Anand Verma, Abdul Q. Jilani, Surya Kant, A study on the prevalence of depression and the severity of depression in patients of chronic obstructive pulmonary disease in a semi-urban Indian population , Monaldi Archives for Chest Disease: Vol. 88 No. 1 (2018)
- M. Lusuardi, F. Blasi, C. Terzano, C. Cricelli, N. Crispino, L. Comarella, F. De Benedetto, C.M. Sanguinetti, L. Allegra, C.F. Donner, Standards of care and clinical predictors in patients hospitalised for a COPD exacerbation - The Italian SOS (Stratification Observational Study) , Monaldi Archives for Chest Disease: Vol. 71 No. 4 (2009): Pulmonary series
- Claudio F. Donner, Sandro Amaducci, Elena Bacci, Sandra Baldacci, Maria L. Bartoli, Gianfranco M. Beghi, Alida Benfante, Sara Brighindi, Lucio Casali, Daniela Castiglia, Mario Cazzola, Alessandro Celi, Silvana Cianchetti, Giorgio Colombo, Claudia Crimi, Federico L. Dente, Giuseppe Di Maria, Annalisa Di Maria, Manuela Latorre, Federico Lavorini, Sara Maio, Claudia Mannini, Riccardo Messina, Pier Luigi Paggiaro, Patrizia Pignatti, David Price, Nicola Scichilone, Marzia Simoni, Antonio Spanevello, Martina Stagno d’Alcontres, Shawna Tan, Roberto Torchio, Giovanni Viegi, Dina Visca, Emiel F.M. Wouters, Shaylynn Yu Hui Xin, Inhalation therapy in the next decade: Determinants of adherence to treatment in asthma and COPD , Monaldi Archives for Chest Disease: Vol. 88 No. 1 (2018)
- P. Trerotoli, N. Bartolomeo, A.M. Moretti, Hospitalisation for COPD in Puglia: the role of hospital discharge database to estimate prevalence and incidence , Monaldi Archives for Chest Disease: Vol. 69 No. 3 (2008): Pulmonary series
- D. Scala, S. Cozzolino, G. D’Amato, G. Cocco, A. Sena, P. Martucci, E. Ferraro, A.A. Mancini, Sharing knowledge is the key to success in a patient-physician relationship: how to produce a patient information leaflet on COPD , Monaldi Archives for Chest Disease: Vol. 69 No. 2 (2008): Pulmonary series
- M. Justine, F. Tahirah, V. Mohan, Health-related quality of life, lung function and dyspnea rating in COPD patients , Monaldi Archives for Chest Disease: Vol. 79 No. 3-4 (2013): Pulmonary series
- Andrea Zanini, Francesca Cherubino, Patrizia Pignatti, The use of roflumilast in COPD: a review , Monaldi Archives for Chest Disease: Vol. 79 No. 3-4 (2013): Pulmonary series - Supplement 1
- A. Kaparianos, F. Sampsonas, D. Lykouras, G. Efremidis, P. Drakatos, K. Karkoulias, C. Gogos, K. Spiropoulos, Association of ET-1 gene polymorphisms with COPD phenotypes in a Caucasian population , Monaldi Archives for Chest Disease: Vol. 75 No. 2 (2011): Pulmonary series
You may also start an advanced similarity search for this article.
